Evidence map›Paper›PMID 33079233›Full record

SynthesisJournal of gastroenterology2021

Verrucous esophageal carcinoma is a unique indolent subtype of squamous cell carcinoma: a systematic review and individual patient regression analysis.

Darrick K Li, Samir Haffar, Masayasu Horibe, Haya A Homsi, Lawrence Zukerberg, Mohammad H Murad, Kavel H Visrodia, Manish Gala, David A Katzka, Fateh Bazerbachi

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Darrick K LiDivision of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Samir HaffarDigestive Center for Diagnosis and Treatment, Damascus, Syrian Arab Republic.
Masayasu HoribeDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku, Tokyo, Japan.
Haya A HomsiSchool of Public Health, University of Waterloo, Waterloo, ON, Canada.
Lawrence ZukerbergDepartment of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Mohammad H MuradEvidence-Based Practice Center, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA.
Kavel H VisrodiaDivision of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Manish GalaClinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA. mgala@mgh.harvard.edu.
David A KatzkaDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Fateh BazerbachiAssistant in Medicine, Instructor in Medicine, Harvard Medical School, Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, GRJ 825D, Boston, MA, 02114, USA. fbazerbachi@mgh.harvard.edu.ORCID http://orcid.org/0000-0003-4599-2042
Harvard University · USMassachusetts General Hospital · USMayo Clinic in Arizona · USKeio University · JPUniversity of Waterloo · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsVerrucous esophageal carcinoma (VEC) is a rare malignancy that presents a diagnostic challenge. We aim to characterize the clinical and genomic features, tumor behavior, and treatment outcomes of VEC to guide clinical practice.

methodsWe performed a systematic review of the literature and identified additional cases from Massachusetts General Hospital records and The Cancer Genome Atlas (TCGA). We obtained individual VEC patient data and analyzed publicly available clinicogenomic data from TCGA. We performed a regression analysis comparing cases of VEC to esophageal squamous cell carcinoma (ESCC) to identify factors influencing survival.

resultsA total of 135 patients were reported in 82 publications, and four unpublished cases from Massachusetts General Hospital (median age 65 years, 69% males, 48% smokers, 33% consumed alcohol). Symptoms were present at diagnosis in 95% of patients, most commonly dysphagia and weight loss. Median symptom onset to diagnosis time was 11.5 months with frequent misdiagnosis as Candida esophagitis. Among VEC cases with pathologic staging, lymph node metastases were rare (5%) compared to ESCC (40%). VEC was genomically characterized by enrichment of SMARCA4 missense mutations and a lack of pathogenic TP53 mutations. Despite its diagnostic elusiveness, in a multivariate regression analysis, VEC was detected at earlier stages (p =  < 0.001) compared to ESCC, and advanced stage was the only significant factor affecting survival (p = 0.013).

conclusionsVEC is a rare, clinically and genomically distinct subtype of ESCC. Recognition and diagnosis of this lesion may allow the pursuit of curative and less morbid treatment strategies.

Indexed as

Carcinoma, VerrucousEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaAdultAgedAged, 80 and overBiomarkers, TumorCombined Modality TherapyDNA HelicasesEarly Detection of CancerFemaleFollow-Up StudiesHumansMaleMiddle AgedMutation, MissenseBiomarkers, TumorDNA HelicasesNuclear ProteinsSMARCA4 protein, humanTP53 protein, humanTranscription FactorsTumor Suppressor Protein p53Endoscopic submucosal dissectionEsophageal squamous cell carcinomaVerrucous esophageal carcinoma

Identifiers

PMID33079233
OpenAlexW3092792644

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.